Track topics on Twitter Track topics that are important to you
An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immune system, which makes it feasible to use asiRNA for the treatment of age-related macular degeneration, a disease to which RNAi therapeutics could not be developed using conventional siRNAs. Other potential applications for BMT's technology include therapeutics targeting infectious disease, such as herpes simplex virus (HSV), and cancer. A privately held company based in Suwon, South Korea, BMT was established in 2010.
Bruker’s Nano Surfaces Division reports on the groundbreaking use of a Dimension FastScan Bio™ AFM system at the University of Leeds, UK, to investigate biological and biomolecular systems at the ...
Most thermodynamic measurements of binding reactions rely on the validity of the law of mass action and the assumption of a dilute solution. Yet, important biological systems such as allosteric ligand...
Regulus Therapeutics San Diego, Californiaheadquartered Regulus Therapeutics Inc.'s stock finished Thursday's session 2.08% lower at $2.35with a total trading volume of 187,480 Read more...
http://stock-callers.com/registration Celldex Therapeutics On Thursday, shares in Hampton, New Jerseyheadquartered Celldex Therapeutics Inc. recorded a trading volume of 3.36 million shares, whi...
Cancer Research UK and its commercialisation arm are to work with UK biotech firm Bicycle Therapeutics on a novel approach to targeting cancer. Bicycle Therapeutics has developed a new class of thera...
NewsMagenta Therapeutics aspires to develop a patient-focused set of therapeutics with the first complete platform that addresses the critical challenges in stem cell transplant.
http://stock-callers.com/registration PTC Therapeutics At the close on Tuesday, shares in South Plainfield, New Jerseyheadquartered PTC Therapeutics Inc. dropped 3.06%, ending the day at Read...
Sosei Group's subsidiary Heptares Therapeutics has agreed to acquire Swiss drugmaker G7 Therapeutics for CHF12m ($11.8m).
Synthetic biology uses living cells as molecular foundries for the biosynthesis of drugs, therapeutic proteins, and other commodities. However, the need for specialized equipment and refrigeration for...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
In this study, DNA sequencing, computational biology modeling, and ex vivo drug sensitivity assays will be utilized to define clinically relevant gene mutations and identify potential ther...
The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.
Prospective, single-arm, open label, Safety and Performance clinical investigation.
Female urinary incontinence and pelvic organ prolapse are common diseases especially in aged women that frequently cause urogenital infection, voiding difficulty, urinary retention, pelvic...
Welcome at the CMBI, which is short for Centre for Molecular and Biomolecular Informatics. The centre performs research and education, and provides services in bioinformatics and cheminformatics.
The Association of Biomolecular Resource Facilities is an international society dedicated to advancing core and research biotechnology laboratories through research, communication, and education.
An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technolo...
Affigen (www.affigen.com) develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain incurable cancers. The Company's growing team ...
A platform nanoparticulate technology for biomolecular delivery in a broad range of industrial, personal use, and biomedical applications.
We have published hundreds of BioMolecular Therapeutics, Inc. news stories on BioPortfolio along with dozens of BioMolecular Therapeutics, Inc. Clinical Trials and PubMed Articles about BioMolecular Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMolecular Therapeutics, Inc. Companies in our database. You can also find out about relevant BioMolecular Therapeutics, Inc. Drugs and Medications on this site too.